meta
|
evidence
oncology
Living systematic review and meta-analysis
malignant mesothelioma (mMS) - 2nd line (L2)
2
multiple myeloma
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus lenalidomide and dexamethasone
pembrolizumab plus pomalidomide and dexamethasone